FDA Lag in mRNA Rare‑Disease Vaccines Signals a Structural Shift in Biotech Regulation
The analysis argues that the FDA's outdated review framework imposes asymmetric costs on mRNA rare‑disease vaccines, reshaping investment flows, career pathways, and…










